The American Journal of Psychiatry
Journal Home Search Current Issue Past Issues Subscribe All APPI Journals Help Contact Us
 
Quicksearch
Advanced Search
Or Search All APPI Journals
This Article
* Full Text (PDF)
* Alert me when this article is cited
* Alert me if a correction is posted
* Citation Map
Services
* Email this article to a Colleague
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Articles & Searches
* Download to citation manager
* reprints & permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Google Scholar
Google Scholar
* Articles by Centorrino, F.
* Articles by Flood, J. G.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Centorrino, F.
* Articles by Flood, J. G.

Am J Psychiatry 1994; 151:123-125
Copyright © 1994 by American Psychiatric Association


BRIEF REPORTS

Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate

F Centorrino, RJ Baldessarini, J Kando, FR Frankenburg, SA Volpicelli, PR Puopolo and JG Flood
Department of Psychiatry, Harvard Medical School, Boston, MA.

Serum concentrations of clozapine, norclozapine, and clozapine-N-oxide were assayed in psychotic patients treated with clozapine alone (N = 17), clozapine with fluoxetine added (N = 6), or clozapine with valproic acid added (N = 11). Subjects were matched for age and other treatments, and concentrations were corrected for daily dose of clozapine (milligrams per kilogram of body weight). With valproic acid, there was a minor increase in total clozapine metabolites, which was even less with dose correction. Fluoxetine increased all clozapine analytes, in some cases to twice the levels in the subjects given only clozapine.


This article has been cited by other articles:


Home page
Br. J. PsychiatryHome page
L. WILLIAMS, G. NEWTON, K. ROBERTS, S. FINLAYSON, and C. BRABBINS
Clozapine-resistant schizophrenia: a positive approach
The British Journal of Psychiatry, September 1, 2002; 181(3): 184 - 187.
[Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
F. Centorrino, B. H. Price, M. Tuttle, W.-M. Bahk, J. Hennen, M. J. Albert, and R. J. Baldessarini
EEG Abnormalities During Treatment With Typical and Atypical Antipsychotics
Am J Psychiatry, January 1, 2002; 159(1): 109 - 115.
[Abstract] [Full Text] [PDF]


Home page
Am. J. PsychiatryHome page
M. P. Freeman and A. L. Stoll
Mood Stabilizer Combinations: A Review of Safety and Efficacy
Am J Psychiatry, January 1, 1998; 155(1): 12 - 21.
[Abstract] [Full Text]


Home page
Drug Metab. Dispos.Home page
J. G. Dain, J. Nicoletti, and F. Ballard
Biotransformation of Clozapine in Humans
Drug Metab. Dispos., May 1, 1997; 25(5): 603 - 609.
[Abstract] [Full Text]


Home page
Journal of Pharmacy PracticeHome page
D. M. Guith
Clozapine: Serious Adverse Side Effects, Drug Interactions, and Other Complications of Therapy
Journal of Pharmacy Practice, April 1, 1996; 9(2): 118 - 129.
[Abstract] [PDF]




Get information about faster international access.

Privacy Policy

Copyright © 1994 American Psychiatric Association. All rights reserved.

Home | Search | Current Issue | Past Issues | Subscribe | All APPI Journals | Help | Contact Us

American Psychiatric Publishing, Inc. American Psychiatric Association
1000 Wilson Boulevard, Suite 1825, Arlington, VA 22209-3901 * 800-368-5777 * appi at psych.org